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Abstract

Background Increasing evidence indicates that alterations to the function and subunit composition of the
glutamatergic NMDA receptor are associated with the pathophysiology of schizophrenia. The GluN2B
protein is a structural and functional subunit of the NMDA receptor, with a growing body of evidence
indicating it plays a critical role in cognitive functions mediated by the NMDA receptor. The hippocampus
plays a key role in cognitive function, with studies suggesting lateralised glutamatergic dysfunction in this
region may contribute to the cognitive deficits observed in schizophrenia patients. The present study, for the
first time, investigated GluN2B protein and binding density in the left and right hippocampus of 20
schizophrenia subjects compared to 20 matched controls. Methods The dentate gyrus of 20 schizophrenia and
20 control subjects, matched for age, post-mortem interval, and pH, was obtained from the NSW Tissue
Resource Centre, Australia. Each group consisted of dentate gyrus from the left hemisphere (n = 10) and right
hemisphere (n = 10). GluN2B protein density was measured via immunoblotting. GluN2B binding density
was measured using the GluN2B antagonist, [3H] Ifenprodil. Analyses of covariance, covarying for
demographic variables that influenced the data, were used to test for statistical significance between
schizophrenia and control groups. Pearson's correlations were used to determine the association of GluN2B
protein and binding density with demographic and clinical variables, including lifetime antipsychotic drug
exposure. Results GluN2B protein levels were decreased by 43% in the left hemisphere of schizophrenia
subjects compared to controls (p = 0.012). There was no difference in GluN2B protein levels in the right
hemisphere of schizophrenia subjects compared to controls. There were no differences in [3H] Ifenprodil
binding according to diagnosis or hemisphere. There were no associations between GluN2B measures and
lifetime antipsychotic drug exposure. Conclusions Our findings provide the first evidence of GluN2 protein
abnormalities in the hippocampus in schizophrenia, highlighting the hippocampal lateralisation in this
disorder. We suggest this deficit could contribute to the cognitive dysfunctions that arise in patients. These
findings provide preliminary support for the development of therapeutics that target the GluN2B subunit, as a
novel therapy for schizophrenia, especially the cognitive dysfunctions.
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Abstract
Background: Increasing evidence indicates that alterations to the function and subunit composition of the
glutamatergic NMDA receptor are associated with the pathophysiology of schizophrenia. The GluN2B protein is a
structural and functional subunit of the NMDA receptor, with a growing body of evidence indicating it plays a
critical role in cognitive functions mediated by the NMDA receptor. The hippocampus plays a key role in cognitive
function, with studies suggesting lateralised glutamatergic dysfunction in this region may contribute to the cognitive
deficits observed in schizophrenia patients. The present study, for the first time, investigated GluN2B protein and
binding density in the left and right hippocampus of 20 schizophrenia subjects compared to 20 matched controls.
Methods: The dentate gyrus of 20 schizophrenia and 20 control subjects, matched for age, post-mortem interval, and
pH, was obtained from the NSW Tissue Resource Centre, Australia. Each group consisted of dentate gyrus from the left
hemisphere (n = 10) and right hemisphere (n = 10). GluN2B protein density was measured via immunoblotting. GluN2B
binding density was measured using the GluN2B antagonist, [3H] Ifenprodil. Analyses of covariance, covarying for
demographic variables that influenced the data, were used to test for statistical significance between schizophrenia
and control groups. Pearson’s correlations were used to determine the association of GluN2B protein and binding
density with demographic and clinical variables, including lifetime antipsychotic drug exposure.
Results: GluN2B protein levels were decreased by 43% in the left hemisphere of schizophrenia subjects compared to
controls (p = 0.012). There was no difference in GluN2B protein levels in the right hemisphere of schizophrenia subjects
compared to controls. There were no differences in [3H] Ifenprodil binding according to diagnosis or hemisphere.
There were no associations between GluN2B measures and lifetime antipsychotic drug exposure.
Conclusions: Our findings provide the first evidence of GluN2 protein abnormalities in the hippocampus in
schizophrenia, highlighting the hippocampal lateralisation in this disorder. We suggest this deficit could contribute to
the cognitive dysfunctions that arise in patients. These findings provide preliminary support for the development of
therapeutics that target the GluN2B subunit, as a novel therapy for schizophrenia, especially the cognitive dysfunctions.
Keywords: GluN2B, NR2B, NMDA receptor, hippocampus, dentate gyrus, human brain

Background
The hippocampus plays an important role in learning
and memory, cognitive functions that are disrupted in
schizophrenia [1]. Several lines of research have shown
that there are various structural and functional abnormalities in the hippocampus of schizophrenia patients,
including a reduction in hippocampal volume, altered
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synaptic connections (evidenced through reductions in
synaptosomal proteins such as synaptophysin, SNAP-25
and synapsin) and changes in neurotransmitter receptors,
implicating the hippocampus in the pathophysiology of
schizophrenia [2].
Dysregulation of glutamatergic neurotransmission, particularly associated with the N-methyl-D-aspartate glutamate receptor (NMDAR) is also widely believed to play
a central role in schizophrenia pathophysiology [3-5]. The
NMDAR is assembled in various subunit combinations,
with obligatory GluN1 subunits coupled primarily with
GluN2A, B, C, or D subunits [6]. Various studies have
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found alterations in NMDAR binding and GluN1 subunit
mRNA and protein in the hippocampus of schizophrenia
subjects (For review see [3]). Some replicated findings include a decrease in GluN1 mRNA in the dentate gyrus of
schizophrenia patients [7,8], a decrease or no change in
NMDAR binding density [7,9,10] and most interestingly a
more pronounced decrease in NMDAR binding and
GluN1 mRNA and protein in the left hippocampus of
schizophrenia subjects compared to the right [8,9,11].
These studies suggest a lateralised glutamatergic dysregulation in the hippocampus of schizophrenia subjects [2].
With regards to the GluN2 subunits, one study has reported an increase in GluN2B mRNA in the hippocampus
in schizophrenia, with two further studies reporting no
change, and no changes have been reported for GluN2A
mRNA, or the less expressed 2C and 2D subunits
[7,10,12]. The status of GluN2 proteins in the hippocampus in schizophrenia is currently unknown, however
one study did report no change in [3H] ifenprodil binding to GluN2B in the hippocampus of schizophrenia
subjects [10]. These aforementioned studies, however,
did not report hemisphere specific analyses which is an
important aspect to consider in studies of the hippocampus [2].
The GluN2 subunit composition defines the functional
properties of the NMDAR [3], therefore to understand
the NMDAR dysregulation in schizophrenia it is critical
to investigate alterations to the GluN2 subunits. GluN2A
and GluN2B are the principle subunits in the hippocampus [13]; evidence suggests that the GluN2B subunit in
the hippocampus is particularly important for NMDAR
channel function [14], long-term potentiation (LTP) and
associated cognitive functions such as spatial learning
[15]. Accordingly, specifically targeting the GluN2B subunit has been suggested as a novel mechanism to treat
cognitive dysfunction in schizophrenia patients and other
cognitive disorders [16,17].
The aim of this study was to determine whether there
are alterations in GluN2B subunit density in the hippocampus of schizophrenia subjects compared to controls
and whether any effects were hemisphere specific. We
used immunoblot to detect GluN2B protein density and
[3H] ifenprodil, which binds to the polyamine site of the
GluN2B subunit, to assess GluN2B binding density.

Methods
Brain Tissue

Post-mortem human brain tissue was acquired from the
NSW Tissue Resource Centre at the University of Sydney.
The cohorts consisted of schizophrenia patients, with the
diagnosis of schizophrenia confirmed according to DSMIV and healthy controls, with no known history of psychiatric illness (Table 1). The cohort for the western blotting
consisted of 20 schizophrenia and 20 control subjects; the

Page 2 of 7

cohort for receptor binding consisted of 20 schizophrenia
and 21 control subjects. There was an overlap of 84% (37/
44) between subjects included in the western blot and
receptor binding studies. There were no significant differences in age, brain pH, post-mortem interval (PMI) or
brain weight between the schizophrenia and control subjects included in the protein or binding studies. This study
was approved by the University of Wollongong Human
Research Ethics Committee (HE99/222).
Immunoblot

Immunoblotting was performed as previously described
[18]. Tissue from the dentate gyrus of the hippocampus
was homogenised in 0.1 M TrisHCl containing 10 μl/ml
protease inhibitor cocktail (Sigma-Aldrich), 0.625 μl/ml
aprotinin and 0.5 μl/ml glycerol. GluN2B protein density
was measured using an anti-GluN2B antibody (#MAB5778,
1/625; Millipore) diluted in PBS-T containing 1% skim milk.
A mouse anti-actin antibody was used as an internal standard (#MAB1501, 1/100 000; Millipore). Samples were run
in triplicate at a concentration of 10 μg of total protein.
GluN2B protein bands were detected on Kodak BioMax
MR Film (Sigma-Aldrich) using enhanced chemiliuminescence reagents (GE Healthcare). Films were analysed using
Quantity One software (BioRad); the optical density of each
band was normalised to the respective β-actin band and averaged over the three runs.
In situ radioligand binding

[3H] Ifenprodil binding was performed based on the
method described previously [19]. Three slides per subject, each containing 14 μm hippocampal sections, were
incubated for 3 hours at 4°C in 0.05 M TrisHCl (pH 7.4)
with 20nM [3H] Ifenprodil (GluN2B antagonist: specific
activity 40 Ci/mmol; PerkinElmer). Due to previous
findings that [3H] ifenprodil has some affinity for sigma
receptors, piperazine acceptor sites, and non-GluN2B
polyamine sites [20-22], the following pharmacological
inhibitors were included in the incubation assay: 3 μM
R(+)-3-(3-hydroxyphenyl)-N-propylpiperidine hydrochloride (+3PPP; to block non-specific binding to the sigma receptor), 30 μM GBR-12909 (to block piperazine sites) and
1 mM trifluoperazine (to block low affinity polyamine sensitive sites on adrenergic, dopaminergic and cholinergic
receptors). Adjacent sections were incubated in the
same solution, with the addition of 20 μM Ifenprodil
(Sigma-Aldrich) to determine any non-specific binding.
All sections were washed in 0.05 M TrisHCl (pH 7.4)
for 3x5 minutes at 4°C, rinsed in distilled water and airdried. All slides were exposed to Kodak BioMax MR
Film (Sigma-Aldrich) for 16 weeks. Films were analysed
using Quantity One software; quantification was performed by taking the average optical density from the dentate gyrus in three slides. Specific binding was determined
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Table 1 Cohort demographic and clinical characteristics
Variable

Cohort

Control

Schizophrenia

n

Western Blot

20

20

Receptor binding

21

20

Age at death

Western Blot

54.5 ± 13.4 (24-73)

54.7 ± 12.8 (27-75)

Mean years ± SD (range)
Post-mortem interval
Mean hours ± SD
pH
Mean ± SD

t

p

-0.036

0.971

Receptor binding

55.3 ± 13.1 (24-73)

54.8 ± 12.8 (27-75)

0.132

0.895

Western Blot

28.2 ± 13.3

29.5 ± 12.5

-0.307

0.761

Receptor binding

30.5 ± 13.6

28.9 ± 12.3

0.388

0.700

Western Blot

6.47 ± 0.35

6.47 ± 0.16

0.069

0.945

Receptor binding

6.44 ± 0.35

6.47 ± 0.16

-0.381

0.706

Gender

Western Blot

12 M/8 F

12 M/8 F

N/A

N/A

Receptor binding

12 M/9 F

12 M/8 F

N/A

N/A

Hemisphere

Western Blot

10 L/10R

11 L/9R

N/A

N/A

Receptor binding

10 L/11R

10 L/10R

N/A

N/A

Brain weight

Western Blot

1410 ± 128

1358 ± 172

1.085

0.285

Receptor binding

1396 ± 139

1358 ± 172

0.792

0.433

Western Blot

N/A

782 ± 543

N/A

N/A

Receptor binding

N/A

809 ± 529

N/A

N/A

Western Blot

N/A

24.1 ± 8.2 (14-44)

N/A

N/A

Mean grams ± SD
Estimated daily antipsychotic drug dose
Mean CPZ equiv ± SD
Age of onset
Mean years ± SD (range)
Duration of illness
Mean years ± SD (range)

Receptor binding

N/A

23.6 ± 8.1 (14-44)

N/A

N/A

Western Blot

N/A

30.6 ± 11.9 (12-47)

N/A

N/A

Receptor binding

N/A

30.7 ± 11.9 (12-47)

N/A

N/A

There was an overlap of 84% (37/44) between subjects included in the western blot and receptor binding studies. Independent t-tests show no significant
differences in age at death, post-mortem interval, pH or brain weight between schizophrenia and control groups; Abbreviations: M, male; F, female; L, left; R, right;
PMI, post-mortem interval; CPZ equiv, chlorpromazine equivalents. N/A, not applicable.

by subtracting non-specific binding density from total
binding density.
Statistical Analyses

The data were checked for triplicate (standard deviation >
30% mean) and population outliers (using box-plots) and
Kolmogorov-Smirnov tests were used to confirm data normality. T-tests, ANOVAs and ANCOVAs with LSD posthoc were used to determine the effects of diagnosis overall
and within the left and right hemispheres, co-varying
for variables that were shown to correlate with the data.
Pearson’s correlations were used to determine relationships to continuous variables including age at death,
PMI, pH, brain weight, antipsychotic medication, age of
illness onset, and duration of illness.

Results
Left hippocampal deficits in GluN2B subunit protein in
schizophrenia subjects

While we observed no overall difference in GluN2B protein density in the dentate gyrus of schizophrenia subjects
compared to controls (t36 = 1.452, p = 0.155), we found a
significant difference between hemisphere-specific subgroups (F3,34 = 2.882, p = 0.050), with a 43% reduction in
GluN2B protein in the left hippocampus of schizophrenia

subjects compared to the left hippocampus of controls
(p = 0.012) and a 40% reduction in GluN2B protein in
the left hippocampus of schizophrenia subjects compared
to the right hippocampus from schizophrenia subjects
(p = 0.023) (Figure 1a and 1b). GluN2B protein density
correlated significantly with brain pH (r = −0.386, p = 0.017)
and there was a trend for a correlation with PMI
(r = −0.318, p = 0.051) in the whole cohort (Table 2). Similar
correlations were observed in the control subjects (pH:
r = −0.662, p = 0.002; PMI: r = −0.483, p = 0.036) but not
the schizophrenia subjects (pH: r = 0.162, p = 0.506; PMI:
r = −0.116, p = 0.636). ANCOVAs correcting for brain pH
and PMI confirmed that there was no overall difference in
GluN2B protein density between schizophrenia and control
subjects (F1,34 = 2.004, p = 0.166) and that there was a significant effect between the 4 hemisphere-specific subgroups
(F3,32 = 3.824, p = 0.019). Importantly, there was no correlation between GluN2B protein density in the schizophrenia
subjects and length of illness, age of disease onset or estimated daily antipsychotic medication dose (Table 2).
No change in GluN2B binding density in schizophrenia
subjects compared to controls

There was no overall difference in [3H] Ifenprodil binding in the dentate gyrus between schizophrenia and
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control subjects (t39 = 0.808, p = 0.424) and no hemisphere
dependent effects (F3,37 = 0.394, p = 0.758) (Figure 1c). [3H]
Ifenprodil binding density correlated with age at death in
the whole cohort (r = −0.309, p = 0.049), showed a trend
towards a correlation in control subjects (r = −0.408,
p = 0.067), but did not correlate in schizophrenia subjects
(r = −0.212, p = 0.369) (Table 2). ANCOVAs to correct for
age at death confirmed no difference in [3H] Ifenprodil
binding density between schizophrenia and control subjects (F1,38 = 0.780, p = 0.383) or hemisphere-specific subgroups (F3,36 = 0.472, p = 0.704). There was no correlation
between GluN2B binding density in the schizophrenia subjects and length of illness, age of disease onset or estimated
daily antipsychotic medication dose (Table 2).

Figure 1 GluN2B protein and binding density in the
hippocampus (dentate gyrus) of schizophrenia and control
subjects. a. GluN2B protein density, normalised to β-actin, in the left
and right hemisphere of schizophrenia (SZ) and control (CT) subjects.
GluN2B was reduced in the left hemisphere of subjects with
schizophrenia, compared to the left hemisphere of controls (−43%,
p = 0.012) and compared to the right hemisphere of schizophrenia
subjects (−40%, p = 0.023 ). *:p < 0.05. b. Representative blot
showing GluN2B and β-actin protein expression in control (CT) and
schizophrenia subjects (SZ) from the left and right hemisphere.
GluN2B was identified as a single band at the expected molecular
weight (175 kDa). c. [3H] Ifenprodil binding to GluN2B revealed no
significant differences between schizophrenia (SZ) and control (CT)
subjects, in the left or right hemisphere. Bars represent mean + SEM.

Discussion
In the present study we have identified a large (43%) reduction in GluN2B protein levels in the hippocampal
dentate gyrus in schizophrenia. This reduction was specific
to the left hemisphere, highlighting the hippocampal lateralisation in the pathophysiology of schizophrenia. In
addition, we have confirmed previous results, this time in a
larger cohort (n = 15 cf. n = 20), indicating no change in
[3H] ifenprodil binding to GluN2B in the hippocampus of
schizophrenia subjects in comparison to controls [10] and
extended these findings to report no hemisphere specific
alteration in GluN2B binding density.
It is well documented that the hippocampus is altered in
schizophrenia and there is evidence to suggest that the left
hemisphere shows more pronounced deficits in NMDAR
expression than the right hemisphere. Previous studies
have reported a more pronounced decrease in GluN1
mRNA and protein in the left hemisphere of schizophrenia
subjects [8,11] as well as a reduction in [123I] CNS-1261
binding to the NMDAR channel in the left hippocampus
of medication free schizophrenia subjects [9]. Ours is the
first study in the hippocampus to report such a lateralisation effect with any of the GluN2 subunits, however, to our
knowledge, the protein density of the other GluN2 subunits has not yet been investigated in this region. It has
previously been reported that deletion of the GluN1 subunit in the CA1 region of the hippocampus results in reduced expression of the GluN2B subunit in the dendrites
of pyramidal neurons in mice [23], suggesting our finding
of reduced GluN2B in the hippocampus could be associated with the reductions in GluN1 previously reported in
the left hippocampus in schizophrenia.
While we found a reduction in GluN2B protein levels
in the present study, this was accompanied by no change
in GluN2B binding density. [3H] Ifenprodil binds to the
polyamine site on GluN2B subunits. While ifenprodil does
also have some affinity for sigma, piperazine, adrenergic
receptors and other polyamine sites [20-22], pharmacological inhibitors were used to block these sites in the
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Table 2 Pearsons correlations for continuous variables influencing GluN2B binding and protein expression in the
hippocampus of all subjects, control subjects only and schizophrenia subjects only
Variable

All subjects

n
Age at death

Control

Schizophrenia

GluN2B

GluN2B

GluN2B

GluN2B

GluN2B

GluN2B

Protein

Binding

Protein

Binding

Protein

Binding

38

41

19

21

19

20

r

0.16

‐0.309

0.207

-0.408

0.152

-0.212

p

0.338

0.049

0.395

0.067

0.534

0.369

Post-mortem interval

r

‐0.318

0.054

‐0.483

0.061

-0.116

0.030

p

0.051

0.738

0.036

0.794

0.636

0.901

pH

r

‐0.386

0.068

‐0.662

0.226

0.162

-0.255

p

0.017

0.671

0.002

0.324

0.506

0.278

Brain weight

r

0.067

-0.029

0.028

0.152

0.023

-0.218

p

0.688

0.855

0.908

0.512

0.926

0.356

r

N/A

N/A

N/A

N/A

-0.056

-0.192

p

N/A

N/A

N/A

N/A

0.819

0.430

r

N/A

N/A

N/A

N/A

0.313

0.007

p

N/A

N/A

N/A

N/A

0.193

0.977

r

N/A

N/A

N/A

N/A

-0.156

-0.368

p

N/A

N/A

N/A

N/A

0.525

0.111

Duration of illness

Age of onset

Estimated daily antipsychotic drug dose

Significant and borderline significant correlations are highlighted in bold. N/A, not applicable.

binding assay. Therefore, it is unlikely that the discrepancy
between binding and protein is a result of [3H] Ifenprodil
binding to non-GluN2B sites. It is possible however that
that these two techniques label different populations of
GluN2B subunits. Under the conditions used in the
present study (i.e. the use of tissue sections rather than
cell lysed homogenates), [3H] ifenprodil would bind primarily to cell surface receptors, while the immunoblot
would detect GluN2B protein in all cellular compartments. This suggests that the reduction observed in
GluN2B protein in the present study might represent a
reduction in intracellular protein levels. The implications of such localised reductions remain unclear [24].
Similar to our study, in cortical brain areas it has been
shown that despite no change in [3H] ifenprodil binding
[25], there was a reduction in GluN2B protein in schizophrenia compared to control subjects, which was specific to the endoplasmic reticulum [26], suggesting there
may be altered production, degradation or trafficking of
GluN2B protein in schizophrenia. While we did not
examine GluN2B mRNA in the present study, two previous studies reported no change in GluN2B mRNA
levels in the dentate gyrus in schizophrenia [10,12],
therefore it is unlikely the findings in the present study
represent changes in GluN2B production. It is possible
however that our findings reflect disturbances to GluN2B
trafficking, degradation, or other aspects of GluN2B regulation. Further studies, specifically examining isolated cellular compartments and proteins that regulate trafficking/

degradation of GluN2B, as well as assessments of GluN2B
phosphorylation and activation would be important to further understand the GluN2B alterations in the hippocampus in schizophrenia.
GluN2B containing NMDARs play a critical role in cognitive functions, especially in the hippocampus (For review see [27]). Selective reduction of GluN2B-containing
NMDARs in the hippocampus has been reported to produce cognitive deficits in rodents [15,28] as well as disrupting underlying molecular processes such as LTP [15].
Specifically, the left hippocampus has previously been associated with verbal and visual memory performance in
schizophrenia subjects [29]. Therefore, a reduction in
NMDARs or altered composition of the NMDAR subunits
in hippocampal subregions, such as that found in the
present study, may be a contributing factor to the cognitive deficits observed in these patients. Therapies aiming to enhance GluN2B function or activity have been
shown to improve cognitive function in animal models
of ageing-induced cognitive impairment [30]. Similarly,
over-expression of GluN2B in transgenic mice results in
increased cognitive ability [31]. Along these lines, positive
allosteric modulation, selective for GluN2B-containing
NMDARs has been proposed as a novel therapeutic strategy for the treatment of schizophrenia and cognitive dysfunction more generally [16,17]. Our finding therefore of
reduced GluN2B protein in the hippocampus, is likely to
contribute to the cognitive symptoms in schizophrenia
patients, and supports the idea that GluN2B positive
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allosteric modulators could potentially be therapeutic for
cognitive dysfunctions in schizophrenia.
As with all post-mortem human brain studies of this
nature, we cannot rule out an influence of ante-mortem
medication on our data. However, we observed no correlation between antipsychotic dose (measured as chlorpromazine equivalents) and GluN2B binding or protein
levels. Furthermore, there is evidence from animal studies
that antipsychotic drug treatment does not alter GluN2B
protein levels in the brain [32-34], suggesting that our findings are unlikely to be due to the effects of pre-mortem
antipsychotic drug treatment.

Conclusion
In conclusion, the present study for the first time revealed
that GluN2B protein levels are significantly decreased
specifically in the left hippocampus (dentate gyrus) of
schizophrenia subjects compared to controls. We suggest
this reduction may be associated with cognitive symptoms
arising in schizophrenia subjects. While further studies are
warranted to determine the functional implications of this
reduction and if this reduction is common to other GluN2
subunits or hippocampal subregions, our findings provide
preliminary support for the development of GluN2B selective positive modulators as a novel therapy for schizophrenia, especially the cognitive dysfunctions.
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